UNICHEMLAB

Unichem Laboratories Share Price

₹857.00 -24.35 (-2.76%)

21 Nov, 2024 14:56

SIP TrendupStart SIP in UNICHEMLAB

Start SIP

Performance

  • Low
  • ₹850
  • High
  • ₹892
  • 52 Week Low
  • ₹401
  • 52 Week High
  • ₹938
  • Open Price₹892
  • Previous Close₹881
  • Volume48,984

Investment Returns

  • Over 1 Month + 16.96%
  • Over 3 Month + 51.75%
  • Over 6 Month + 52.72%
  • Over 1 Year + 104.19%
SIP Lightning

Smart Investing Starts Here Start SIP with Unichem Laboratories for Steady Growth!

Invest Now

Unichem Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -1082.8
  • PEG Ratio
  • -11.3
  • Market Cap Cr
  • 6,034
  • P/B Ratio
  • 2.6
  • Average True Range
  • 45.59
  • EPS
  • 7.11
  • Dividend Yield
  • 0
  • MACD Signal
  • 49.16
  • RSI
  • 65.98
  • MFI
  • 44.31

Unichem Laboratories Financials

Unichem Laboratories Technicals

EMA & SMA

Current Price
₹857.00
-24.35 (-2.76%)
pointer
  • stock-down_img
  • Bullish Moving Average 11
  • stock-up_img
  • Bearish Moving Average 5
  • 20 Day
  • ₹842.47
  • 50 Day
  • ₹760.06
  • 100 Day
  • ₹684.99
  • 200 Day
  • ₹608.63

Resistance and Support

886.6 Pivot Speed
  • R3 928.30
  • R2 916.15
  • R1 898.75
  • S1 869.20
  • S2 857.05
  • S3 839.65

What's your outlook on Unichem Laboratories?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Unichem Laboratories Ltd. is a leading Indian pharmaceutical company specializing in the manufacturing of Active Pharmaceutical Ingredients (APIs) and formulations. It serves domestic and international markets with a focus on quality, research, and innovative healthcare solutions.

Unichem Laboratories has an operating revenue of Rs. 1,774.67 Cr. on a trailing 12-month basis. An annual revenue growth of 26% is outstanding, Pre-tax margin of -4% needs improvement, ROE of -2% is poor and needs improvement. The company has a reasonable debt to equity of 2%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 19% and 49% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 64 which is a FAIR score but needs to improve its earnings, a RS Rating of 89 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 39 indicates it belongs to a strong industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Unichem Laboratories Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-13 Quarterly Results
2024-09-30 Others
2024-08-08 Quarterly Results
2024-05-22 Audited Results
2024-02-05 Quarterly Results

Unichem Laboratories F&O

Unichem Laboratories Shareholding Pattern

70.22%
10.22%
0.22%
0.94%
0.03%
14.58%
3.79%

About Unichem Laboratories

  • NSE Symbol
  • UNICHEMLAB
  • BSE Symbol
  • 506690
  • Managing Director
  • Mr. Pabitrakumar Bhattacharyya
  • ISIN
  • INE351A01035

Similar Stocks to Unichem Laboratories

Unichem Laboratories FAQs

Unichem Laboratories share price is ₹857 As on 21 November, 2024 | 14:42

The Market Cap of Unichem Laboratories is ₹6033.8 Cr As on 21 November, 2024 | 14:42

The P/E ratio of Unichem Laboratories is -1082.8 As on 21 November, 2024 | 14:42

The PB ratio of Unichem Laboratories is 2.6 As on 21 November, 2024 | 14:42

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23